Drug-induced gingival hyperplasia in transplant recipients

Progress in Transplantation

Volumn 12, Issue 1, 2002, Pages 17-23

  Hood, Kerri A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; CYCLOSPORIN; METRONIDAZOLE; NIFEDIPINE; PHENYTOIN; TACROLIMUS; VERAPAMIL;

ANTIBIOTIC THERAPY; ARTICLE; DISEASE SEVERITY; EXCISION; GINGIVA HYPERPLASIA; GINGIVA OVERGROWTH; HUMAN; LASER SURGERY; MOUTH HYGIENE; ORGAN TRANSPLANTATION; PATHOGENESIS; PREVENTION; RECIPIENT;

EID: 0036125999     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.7182/prtr.12.1.k0605089820vt807     Document Type: Article

References (52)

1. Calcium antagonist induced gingival hyperplasia
2. Gingival hyperplasia: A side effect of nifedipine and diltiazem
3. Incidence of verapamil-induced gingival hyperplasia in a dental population
4. Prevalence of amlodipine-related gingival hyperplasia
5. Felodipine-induced gingival hyperplasia: A clinical and histologic study
6. Nitrendipine induced gingival hyperplasia: First case report
7. Felodipine-induced gingival hyperplasia
8. Drug-induced gingival hyperplasia: Phenytoin, cyclosporine, and nifedipine
9. Medically induced gingival hyperplasia
10. Complications of CyA: A comparison to azathioprine
11. Evaluation of cyclosporin-induced gingival overgrowth in the pediatric transplant patient
12. Gingival overgrowth in cyclosporine A treated multiple sclerosis patients
13. Impact of cyclosporine A pharmacokinetics on the presence of side effects in pediatric renal transplantation
14. On the mechanism of drug-induced gingival hyperplasia
15. Risk factors in the development of cyclosporine-induced gingival overgrowth
16. Drug-induced gingival overgrowth and class II major histo compatibility antigens
17. Pre-transplant gingival hyperplasia predicts severe cyclosporin-induced gingival overgrowth in renal transplant patients
18. The pathogenesis of drug-induced gingival overgrowth
19. The prevalence and severity of cyclosporin and nifedipine-induced gingival overgrowth
20. Crevicular fluid interleukin-1β, tumor necrosis factor-α, and interleukin-6 levels in renal transplant patients receiving cyclosporine A
21. Cyclosporin A regulates interleukin-1β and interleukin-6 expression in gingiva: Implications for gingival overgrowth
22. Phenytoin and cyclosporine A specifically regulate macrophage phenotype and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: Possible molecular mechanism of drug induced gingival hyperplasia
23. 4 and platelet activating factor in gingival crevicular fluid in renal transplant patients receiving cyclosporine A
24. The effect of plaque control programme on the incidence and severity of cyclosporin-induced gingival changes
25. The effects of chlorhexidine and mechanical methods of plaque control on the recurrence of gingival hyperplasia in young patients taking phenytoin
26. Cyclosporine induced gingival hyperplasia and chlorhexidine: A case report
27. Study of the effects of the drug FK506 on gingival tissues
28. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection
29. Tacrolimus and gingival hyperplasia
30. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol
31. Conversion from cyclosporine to tacrolimus in renal transplant recipients with gum hyperplasia
32. Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients
33. Conversion from neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis
34. Reduction of cyclosporine-induced gingival overgrowth following a change to tacrolimus: A case history involving a liver transplant patient
35. Treatment of cyclosporine-induced gingival hypertrophy
36. Resolution of cyclosporin-induced gingival hypertrophy with metronidazole
37. Oral metronidazole does not improve cyclosporine A-induced gingival hyperplasia
38. Improvement in cyclosporine-associated gingival hyperplasia with azithromycin therapy
39. Improvement in cyclosporine A associated gingival hyperplasia with azithromycin therapy
40. Treatment of gingival hyperplasia secondary to cyclosporine by the new macrolide azithromycin
41. Effect of antibiotic treatment with azithromycin on cyclosporine A-induced gingival hyperplasia among renal transplant recipients
42. Treatment of cyclosporine-induced gingival hyperplasia with azithromycin
43. Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients
44. Clarithromycin in the treatment of cyclosporin-associated gingival hyperplasia
45. The interaction between clarithromycin and cyclosporine in kidney transplant recipients
46. Interaction between azithromycin and cyclosporin?
47. Azithromycin in the treatment of periodontal disease: Effect on microbial flora
48. Intracellular accumulation of azithromycin by cultured human fibroblasts
49. Surgical treatment of cyclosporine A- and nifedipine-induced gingival enlargement: Gingivectomy versus periodontal flap
50. Use of an argon laser to treat drug-induced gingival overgrowth
51. Combined treatment approach to gingival overgrowth due to drug therapy
52. Drug-induced gingival hyperplasia and its management: A literature review